Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Both animal models [1, 3] and clinical trials [4, 5] have shown that antiCTLA-4 treatment resulted in enhanced T cell responses, which led to anti-tumor responses and survival benefit.”
BackgroundResultSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511 · cited 2×
“Grade 3–4 irAEs associated with ipilimumab treatment include 15% diarrhea, 5% colitis, 4% liver enzyme elevation, and 1% endocrinopathy [10].”
BackgroundSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 1×
“Previous data have also indicated that anti-CTLA-4 can lead to decrease in regulatory T cells [35] which may lead to diminished immunosuppression and potentiation of irAEs.”
BackgroundManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · cited 2×
“In patients who developed colitis after ipilimumab treatment, biopsy of the colon in the areas with active colitis revealed infiltration of neutrophils, T lymphocytes, and plasma cells [27, 28, 30].”
BackgroundQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“Monoclonal antibodies that block the immune checkpoint molecule, CTLA-4, have been shown to potentiate T cell activation against a variety of tumors [1, 3, 7, 8].”
BackgroundIpilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320 · cited 3×
“The spectrum of irAEs ranges from common reactions, such as dermatitis, colitis, hepatitis, and hypophysitis, to rare conditions such as uveitis, neuropathy, and lupus nephritis [6, 12, 13].”
Background
Cited by
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Self-citationGao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Self-citationAbdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444
Self-citationSubudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
“Although most of the severe irAEs can be reversed with high-dose steroids and/or other immunosuppressive therapies, they often require protracted courses of immunosuppression, which frequently results in additional complications and significant morbidities (13).”
BackgroundSelf-citationSubudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158
Metadata
- Authors
- Gao, J., He, Q., Subudhi, S., Aparicio, A., Zurita-Saavedra, A., Lee, D. H., Jimenez, C., Suarez-Almazor, M., & Sharma, P.
- Venue
- Oncogene
- Published
- 2015-02-09
- Volume
- 34
- Issue
- 43
- Pages
- 5411-5417
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1987030266
- Cited by
- 49
- References
- 11
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. https://app.cochat.ai/papers/10.1038/onc.2015.5
- The paper
- Gao, J., He, Q., Subudhi, S., Aparicio, A., Zurita-Saavedra, A., Lee, D. H., Jimenez, C., Suarez-Almazor, M., & Sharma, P. (2015). Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. https://doi.org/10.1038/onc.2015.5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.